Home > Research > Publications & Outputs > Counteracting bone fragility with amniotic flui...

Links

Text available via DOI:

View graph of relations

Counteracting bone fragility with amniotic fluid-derived fetal stem cells

Research output: Contribution to journalJournal article

Published

Standard

Counteracting bone fragility with amniotic fluid-derived fetal stem cells. / Ranzoni, Anna; Corcelli, Michelangelo; Hau, Kwan-Leong ; Kerns, Jemma Gillian; Vanleene, Maximillien; Shefelbine, Sandra; Jones, Gemma; Moschidou, Dafni; Dala-Ali, Benan; Goodship, Allen; Arnett, Timothy; Guillot, Pascale.

In: Scientific Reports, Vol. 6, 39656, 20.12.2016.

Research output: Contribution to journalJournal article

Harvard

Ranzoni, A, Corcelli, M, Hau, K-L, Kerns, JG, Vanleene, M, Shefelbine, S, Jones, G, Moschidou, D, Dala-Ali, B, Goodship, A, Arnett, T & Guillot, P 2016, 'Counteracting bone fragility with amniotic fluid-derived fetal stem cells', Scientific Reports, vol. 6, 39656. https://doi.org/10.1038/srep39656

APA

Ranzoni, A., Corcelli, M., Hau, K-L., Kerns, J. G., Vanleene, M., Shefelbine, S., Jones, G., Moschidou, D., Dala-Ali, B., Goodship, A., Arnett, T., & Guillot, P. (2016). Counteracting bone fragility with amniotic fluid-derived fetal stem cells. Scientific Reports, 6, [39656]. https://doi.org/10.1038/srep39656

Vancouver

Ranzoni A, Corcelli M, Hau K-L, Kerns JG, Vanleene M, Shefelbine S et al. Counteracting bone fragility with amniotic fluid-derived fetal stem cells. Scientific Reports. 2016 Dec 20;6. 39656. https://doi.org/10.1038/srep39656

Author

Ranzoni, Anna ; Corcelli, Michelangelo ; Hau, Kwan-Leong ; Kerns, Jemma Gillian ; Vanleene, Maximillien ; Shefelbine, Sandra ; Jones, Gemma ; Moschidou, Dafni ; Dala-Ali, Benan ; Goodship, Allen ; Arnett, Timothy ; Guillot, Pascale. / Counteracting bone fragility with amniotic fluid-derived fetal stem cells. In: Scientific Reports. 2016 ; Vol. 6.

Bibtex

@article{044f1a92e7c440da84b2c70718d51e35,
title = "Counteracting bone fragility with amniotic fluid-derived fetal stem cells",
abstract = "The impaired maturation of bone-forming osteoblasts results in reduced bone formation and subsequent bone weakening, which leads to a number of conditions such as osteogenesis imperfecta (OI). Transplantation of human fetal mesenchymal stem cells has been proposed as skeletal anabolic therapy to enhance bone formation, but the mechanisms underlying the contribution of the donor cells to bone health are poorly understood and require further elucidation. Here, we show that intraperitoneal injection of human amniotic mesenchymal stem cells (AFSCs) into a mouse model of OI (oim mice) reduced fracture susceptibility, increased bone strength, improved bone quality and micro-architecture, normalised bone remodelling and reduced TNFα and TGFβ sigalling. Donor cells engrafted into bones and differentiated into osteoblasts but importantly, also promoted endogenous osteogenesis and the maturation of resident osteoblasts. Together, these findings identify AFSC transplantation as a countermeasure to bone fragility. These data have wider implications in for bone health and fracture reduction.",
keywords = "Mesenchymal stem cells, Regeneration",
author = "Anna Ranzoni and Michelangelo Corcelli and Kwan-Leong Hau and Kerns, {Jemma Gillian} and Maximillien Vanleene and Sandra Shefelbine and Gemma Jones and Dafni Moschidou and Benan Dala-Ali and Allen Goodship and Timothy Arnett and Pascale Guillot",
year = "2016",
month = dec
day = "20",
doi = "10.1038/srep39656",
language = "English",
volume = "6",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",

}

RIS

TY - JOUR

T1 - Counteracting bone fragility with amniotic fluid-derived fetal stem cells

AU - Ranzoni, Anna

AU - Corcelli, Michelangelo

AU - Hau, Kwan-Leong

AU - Kerns, Jemma Gillian

AU - Vanleene, Maximillien

AU - Shefelbine, Sandra

AU - Jones, Gemma

AU - Moschidou, Dafni

AU - Dala-Ali, Benan

AU - Goodship, Allen

AU - Arnett, Timothy

AU - Guillot, Pascale

PY - 2016/12/20

Y1 - 2016/12/20

N2 - The impaired maturation of bone-forming osteoblasts results in reduced bone formation and subsequent bone weakening, which leads to a number of conditions such as osteogenesis imperfecta (OI). Transplantation of human fetal mesenchymal stem cells has been proposed as skeletal anabolic therapy to enhance bone formation, but the mechanisms underlying the contribution of the donor cells to bone health are poorly understood and require further elucidation. Here, we show that intraperitoneal injection of human amniotic mesenchymal stem cells (AFSCs) into a mouse model of OI (oim mice) reduced fracture susceptibility, increased bone strength, improved bone quality and micro-architecture, normalised bone remodelling and reduced TNFα and TGFβ sigalling. Donor cells engrafted into bones and differentiated into osteoblasts but importantly, also promoted endogenous osteogenesis and the maturation of resident osteoblasts. Together, these findings identify AFSC transplantation as a countermeasure to bone fragility. These data have wider implications in for bone health and fracture reduction.

AB - The impaired maturation of bone-forming osteoblasts results in reduced bone formation and subsequent bone weakening, which leads to a number of conditions such as osteogenesis imperfecta (OI). Transplantation of human fetal mesenchymal stem cells has been proposed as skeletal anabolic therapy to enhance bone formation, but the mechanisms underlying the contribution of the donor cells to bone health are poorly understood and require further elucidation. Here, we show that intraperitoneal injection of human amniotic mesenchymal stem cells (AFSCs) into a mouse model of OI (oim mice) reduced fracture susceptibility, increased bone strength, improved bone quality and micro-architecture, normalised bone remodelling and reduced TNFα and TGFβ sigalling. Donor cells engrafted into bones and differentiated into osteoblasts but importantly, also promoted endogenous osteogenesis and the maturation of resident osteoblasts. Together, these findings identify AFSC transplantation as a countermeasure to bone fragility. These data have wider implications in for bone health and fracture reduction.

KW - Mesenchymal stem cells

KW - Regeneration

U2 - 10.1038/srep39656

DO - 10.1038/srep39656

M3 - Journal article

VL - 6

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

M1 - 39656

ER -